α-干扰素诱导的树突状细胞在恶性脑胶质瘤患者治疗中的应用。

Use of interferon-alpha-induced dendritic cells in the therapy of patients with malignant brain gliomas.

作者信息

Leplina O Yu, Stupak V V, Kozlov Yu P, Pendyurin I V, Nikonov S D, Tikhonova M A, Sycheva N V, Ostanin A A, Chernykh E R

机构信息

Institute of Clinical Immunology, Siberian Division of Russian Academy of Medical Sciences.

出版信息

Bull Exp Biol Med. 2007 Apr;143(4):528-34. doi: 10.1007/s10517-007-0172-1.

DOI:10.1007/s10517-007-0172-1

PMID:18214316

Abstract

Clinical and immunological analysis of the efficiency of combined immunotherapy with the use dendritic cells for the treatment of malignant glioma of the brain was carried out. Dendritic cells generated in the presence of granulocyte-macrophage CSF and IFN-alpha retain their functional characteristics in patients with gliomas, which suggests the possibility of their use for the treatment of malignant tumors (glioma) of the brain. Combined therapy using interferon-induced dendritic cells was associated with generation of antigen-specific immune response during vaccinations. The results indicate satisfactory tolerance of combined immunotherapy using dendritic cells and the absence of toxic side effects at the stage of adoptive immunotherapy and at the stage of vaccinations with dendritic cells. Clinical trials showed that vaccinations with dendritic cells included into combined immunotherapy improved the quality of life and survival of patients with malignant gliomas.

摘要

开展了使用树突状细胞的联合免疫疗法治疗脑恶性胶质瘤疗效的临床及免疫学分析。在粒细胞巨噬细胞集落刺激因子（CSF）和α干扰素存在的情况下产生的树突状细胞，在胶质瘤患者中保留了其功能特性，这表明它们可用于治疗脑恶性肿瘤（胶质瘤）。使用干扰素诱导的树突状细胞的联合疗法与接种疫苗期间抗原特异性免疫反应的产生有关。结果表明，使用树突状细胞的联合免疫疗法耐受性良好，在过继性免疫疗法阶段和用树突状细胞接种疫苗阶段均无毒性副作用。临床试验表明，联合免疫疗法中使用树突状细胞进行接种可改善恶性胶质瘤患者的生活质量和生存率。